142 related articles for article (PubMed ID: 32710697)
1. Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients.
Barr EK; Laurie K; Wroblewski K; Applebaum MA; Cohn SL
Pediatr Blood Cancer; 2020 Oct; 67(10):e28390. PubMed ID: 32710697
[TBL] [Abstract][Full Text] [Related]
2. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
3. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
Pearson AD; Pinkerton CR; Lewis IJ; Imeson J; Ellershaw C; Machin D; ;
Lancet Oncol; 2008 Mar; 9(3):247-56. PubMed ID: 18308250
[TBL] [Abstract][Full Text] [Related]
4. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Park JR; Bagatell R; Cohn SL; Pearson AD; Villablanca JG; Berthold F; Burchill S; Boubaker A; McHugh K; Nuchtern JG; London WB; Seibel NL; Lindwasser OW; Maris JM; Brock P; Schleiermacher G; Ladenstein R; Matthay KK; Valteau-Couanet D
J Clin Oncol; 2017 Aug; 35(22):2580-2587. PubMed ID: 28471719
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study.
Bagatell R; McHugh K; Naranjo A; Van Ryn C; Kirby C; Brock P; Lyons KA; States LJ; Rojas Y; Miller A; Volchenboum SL; Simon T; Krug B; Sarnacki S; Valteau-Couanet D; von Schweinitz D; Kammer B; Granata C; Pio L; Park JR; Nuchtern J
J Clin Oncol; 2016 Mar; 34(7):740-6. PubMed ID: 26755515
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting.
Castel V; García-Miguel P; Cañete A; Melero C; Navajas A; Ruíz-Jiménez JI; Navarro S; Badal MD
Eur J Cancer; 1999 Apr; 35(4):606-11. PubMed ID: 10492635
[TBL] [Abstract][Full Text] [Related]
7. Role of surgery in the treatment of patients with high-risk neuroblastoma who have a poor response to induction chemotherapy.
Du L; Liu L; Zhang C; Cai W; Wu Y; Wang J; Lv F
J Pediatr Surg; 2014 Apr; 49(4):528-33. PubMed ID: 24726106
[TBL] [Abstract][Full Text] [Related]
8. Predictors of survival in patients with high-risk neuroblastoma who failed tandem high-dose chemotherapy and autologous stem cell transplantation.
Yi ES; Son MH; Hyun JK; Cho HW; Ju HY; Lee JW; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2020 Feb; 67(2):e28066. PubMed ID: 31736249
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
10. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
Villablanca JG; Ji L; Shapira-Lewinson A; Marachelian A; Shimada H; Hawkins RA; Pampaloni M; Lai H; Goodarzian F; Sposto R; Park JR; Matthay KK
Pediatr Blood Cancer; 2018 May; 65(5):e26940. PubMed ID: 29350464
[TBL] [Abstract][Full Text] [Related]
11. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
Brodeur GM; Pritchard J; Berthold F; Carlsen NL; Castel V; Castelberry RP; De Bernardi B; Evans AE; Favrot M; Hedborg F
J Clin Oncol; 1993 Aug; 11(8):1466-77. PubMed ID: 8336186
[TBL] [Abstract][Full Text] [Related]
12. The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma.
Yoo SY; Kim JS; Sung KW; Jeon TY; Choi JY; Moon SH; Son MH; Lee SH; Yoo KH; Koo HH
Cancer; 2013 Feb; 119(3):656-64. PubMed ID: 22952047
[TBL] [Abstract][Full Text] [Related]
13. Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.
Holmes K; Pötschger U; Pearson ADJ; Sarnacki S; Cecchetto G; Gomez-Chacon J; Squire R; Freud E; Bysiek A; Matthyssens LE; Metzelder M; Monclair T; Stenman J; Rygl M; Rasmussen L; Joseph JM; Irtan S; Avanzini S; Godzinski J; Björnland K; Elliott M; Luksch R; Castel V; Ash S; Balwierz W; Laureys G; Ruud E; Papadakis V; Malis J; Owens C; Schroeder H; Beck-Popovic M; Trahair T; Forjaz de Lacerda A; Ambros PF; Gaze MN; McHugh K; Valteau-Couanet D; Ladenstein RL;
J Clin Oncol; 2020 Sep; 38(25):2902-2915. PubMed ID: 32639845
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Tushabe DA; Berthold F
Cochrane Database Syst Rev; 2015 Jan; 1():CD010685. PubMed ID: 25634649
[TBL] [Abstract][Full Text] [Related]
15. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
[No Abstract] [Full Text] [Related]
17. Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes.
Avanzini S; Pio L; Erminio G; Granata C; Holmes K; Gambart M; Buffa P; Castel V; Valteau Couanet D; Garaventa A; Pistorio A; Cecchetto G; Martucciello G; Mattioli G; Sarnacki S
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28440012
[TBL] [Abstract][Full Text] [Related]
18. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.
Ladenstein R; Philip T; Lasset C; Hartmann O; Garaventa A; Pinkerton R; Michon J; Pritchard J; Klingebiel T; Kremens B; Pearson A; Coze C; Paolucci P; Frappaz D; Gadner H; Chauvin F
J Clin Oncol; 1998 Mar; 16(3):953-65. PubMed ID: 9508178
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of induction chemotherapy regimens for high-risk neuroblastoma in South African children
Van Heerden J; Geel J; Hendricks M; Wouters K; Büchner A; Naidu G; Hadley GP; Du Plessis J; Van Emmenes B; Van Zyl A; Vermeulen J; Kruger M
Pediatr Hematol Oncol; 2020 May; 37(4):300-313. PubMed ID: 32075464
[TBL] [Abstract][Full Text] [Related]
20. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
